Vaccines in historic evolution and perspective: A narrative of vaccine discoveries

Vaccine

Volumn 18, Issue 15, 2000, Pages 1436-1447

  Hilleman, Maurice R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

History of vaccines

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; CHICKENPOX VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MUMPS VACCINE; RUBELLA VACCINE; VACCINE; VIRUS VACCINE;

BIRD DISEASE; CELL CULTURE; CONFERENCE PAPER; COWPOX VIRUS; DRUG RESEARCH; HUMAN; NONHUMAN; PRIORITY JOURNAL; RICKETTSIA; SMALLPOX; VACCINATION;

BACTERIAL VACCINES; HEPATITIS A VACCINES; HEPATITIS B VACCINES; HISTORY, 20TH CENTURY; HUMANS; POLIOVIRUS VACCINE, INACTIVATED; VACCINES; VIRAL HEPATITIS VACCINES;

EID: 0033979937     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00434-X     Document Type: Conference Paper

References (79)

1. Hilleman M.R. Six decades of vaccine development - a personal history. Nat. Med. 4:((Vaccine Suppl.)):1998;507-514.
2. Hilleman M.R. Personal historical chronicle of six decades of basic and applied research in virology, immunology and vaccinology. Immunol. Rev. (in press).
3. Castiglioni A. Knopf A.A. A history of medicine. 1958;Knopf, New York. (Krumbhaar EB. Trans.).
4. Plotkin M.S.L.S., Plotkin S.A. A short history of vaccination. Plotkin S.A., Mortimer E.A. Vaccines. 1988;1-7 Saunders, Philadelphia.
5. Jenner E. An inquiry into the causes and effects of the variolae vaccinae. 1798;Low, London.
6. Burke D.S., Auzias-Turenne J.-A. Louis Pasteur and early concepts of virulence attenuation and vaccination. Perspect. Biol. Med. 39:1996;171-186.
7. Sabin A.B. The St. Louis and Japanese B types of epidemic encephalitis. Development of noninfective vaccines: report of basic data. J. Am. Med. Assoc. 122:1943;478-486.
8. Hilleman M.R., Mason R.P., Rogers N.G. Laboratory studies on the 1950 outbreak of influenza. Public Health Rep. 65:1950;771-777.
9. Hilleman M.R., Mason R.P., Buescher E.L. Antigenic pattern of strains of influenza A and B. Proc. Soc. Exp. Biol. Med. 75:1950;829-835.
10. Hilleman M.R., Werner J.H., Gauld R.L. Serological studies of influenza antibodies in the population of the United States: an epidemiological investigation. Bull. WHO. 8:1953;613-631.
11. Webster R.G. Influenza viruses. Webster R.G., Granoff A. Encyclopedia of virology. vol. 2:1994;709-727 Academic Press, New York.
12. Meyer H.M. Jr., Hilleman M.R., Miesse M.L., Crawford I.P., Bankhead A.S. New antigenic variant in Far East influenza epidemic, 1957. Proc. Soc. Exp. Biol. Med. 95:1957;609-616.
13. Hilleman M.R. Status report on adenoviruses and Asian influenza. Mil. Med. 123:1958;23-30.
14. Hilleman M.R., Flatley F.J., Anderson S.A., Luecking M.L., Levinson D.J. Antibody response in volunteers to Asian influenza vaccine. J. Am. Med. Assoc. 166:1958;1134-1140.
15. Hilleman M.R., Werner J.H. Recovery of new agent from patients with acute respiratory illness. Proc. Soc. Exp. Biol. Med. 85:1954;183-188.
16. Hilleman M.R., Werner J.H., Dascomb H.E., Butler R.L., Stewart M.T. Epidemiology of RI (RI-67) group respiratory virus infections in recruit populations. Am. J. Hygiene. 62:1955;29-43.
17. Rowe W.P., Huebner R.J., Gilmore L.K., Parrott R.H., Ward T.G. Isolation of a cytopathic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Biol. Med. 84:1953;570-573.
18. Enders J.F., Weller T.H., Robbins F.C. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various embryonic tissues. Science. 109:1949;85-87.
19. Hilleman M.R., Stallones R.A., Gauld R.L., Warfield M.S., Anderson S.A. Prevention of acute respiratory illness in recruits by adenovirus (RI-APC-ARD) vaccine. Proc. Soc. Exp. Biol. Med. 92:1956;377-383.
20. Stallones R.A., Hilleman M.R., Gauld R.L., Warfield M.S., Anderson S.A. Adenovirus (RI-APC-ARD) vaccine for prevention of acute respiratory illness. 2. Field evaluation. J. Am. Med. Assoc. 163:1957;9-15.
21. Austrian R. Pneumococcus the first 100 years. Rev. Infect. Dis. 3:1981;183-189.
22. Smit P., Oberholzer D., Hayden-Smith S., Koornhof H.J., Hilleman M.R. Protective efficacy of pneumococcal vaccines. J. Am. Med. Assoc. 238:1977;2613-2616.
23. Hilleman M.R., McLean A.A., Vella P.P., Weibel R.E., Woodhour A.F. Polyvalent pneumococcal polysaccharide vaccines. J. Infect. 1:1979;1-16.
24. Gotschlich E.C., Liu T.Y., Artenstein M.S. Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J. Exp. Med. 129:1969;1349-1365.
25. Weibel R.E., Villarejos V.M., Vella P.P., Woodhour A.F., McLean A.A., Hilleman M.R. Clinical and laboratory investigations of monovalent and combined meningococcal polysaccharide vaccines Groups A and C. Proc. Soc. Exp. Biol. Med. 153:1976;436-440.
26. Tai J.Y., et al. Haemophilus influenzae Type b polysaccharide-protein conjugate vaccine. Proc. Soc. Exp. Biol. Med. 184:1987;154-161.
27. Santosham M., et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilua influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. New Engl. J. Med. 324:1991;1767-1772.
28. Lyme disease vaccine cleared for marketing. Am. J. Health - Syst. Pharm. 56:1999;208.
29. Sweet B.H., Hilleman M.R. The vacuolating virus, SV40. Proc. Soc. Exp. Biol. Med. 105:1960;420-427.
30. 40) and its relationship to poliomyelitis virus vaccines. Dev. Biol. Stand. 94:1998;183-190.
31. 40. Proc. Soc. Exp. Biol. Med. 109:1962;649-660.
32. Hilleman M.R., et al. Investigation into the development and clinical testing of a poliomyelitis vaccine containing standardized amounts of purified poliomyelitis virus antigens. Acad. Med. N. J. Special Bull. 6:1960;1-31.
33. Melnick J.L. Live attenuated poliovaccines. Plotkin S.A., Mortimer E.A. Vaccines. 1988;115-157 Saunders, Philadelphia.
34. Stokes J. Jr., Weibel R., Halenda R., Reilly C.M., Hilleman M.R. Studies of live attenuated measles virus vaccine in man. 1. Clinical aspects. Am. J. Public Health. 52:1962;29-43.
35. Hilleman M.R., Stokes J. Jr., Buynak E.B., Weibel R., Halenda R., Goldner H. Studies of live attenuated measles virus in man. 2. Appraisal of efficacy. Am. J. Public Health. 52:1962;44-56.
36. Hughes W.F., Watanabe D.H., Rubin H. The development of a chicken flock apparently free of leukosis virus. Avian. Dis. 7:1963;154-165.
37. Hilleman M.R., Buynak E.B., Weibel R.E., Stokes J. Jr., Whitman J.E. Jr., Leagus M.B. Development and evaluation of the Moraten measles virus vaccine. J. Am. Med. Assoc. 206:1968;587-590.
38. Buynak E.B., Hilleman M.R. Live attenuated mumps virus vaccine 1. Vaccine development. Proc. Soc. Exp. Biol. Med. 123:1966;768-775.
39. Hilleman M.R., Weibel R.E., Buynak E.B., Stokes J. Jr., Whitman J.E. Jr. Live attenuated mumps virus vaccine. 4. Protective efficacy measured in field evaluation. New Engl. J. Med. 276:1967;252-258.
40. Buynak E.B., Larson V.M., McAleer W.J., Mascoli C.C., Hilleman M.R. Preparation and testing of duck embryo cell culture rubella vaccine. Am. J. Dis. Child. 118:1969;347-354.
41. Hilleman M.R., Buynak E.B., Whitman J.E. Jr., Weibel R.E., Stokes J. Jr. Live attenuated rubella virus vaccines. Experiences with duck embryo cell preparations. Am. J. Dis. Child. 118:1969;166-171.
42. Weibel R.E., Stokes J. Jr., Buynak E.B., Hilleman M.R. Live rubella vaccines in adults and children. HPV-77 and Merck-Benoit strains. Am. J. Dis. Child. 118:1969;226-229.
43. Hilleman M.R., Buynak E.B., Weibel R.E., Stokes J. Jr. Current concepts: live attenuated rubella-virus vaccine. New Engl. J. Med. 279:1968;300-303.
44. Stokes J. Jr., Weibel R.E., Buynak E.B., Hilleman M.R. Protective efficacy of duck embryo rubella vaccines. Pediatrics. 44:1969;217-224.
45. Buynak E.B., Weibel R.E., Whitman J.E. Jr., Stokes J. Jr., Hilleman M.R. Combined live measles mumps and rubella virus vaccines. J. Am. Med. Assoc. 207:1969;2259-2262.
46. Stokes J. Jr., Weibel R.E., Villarejos V.M., Arguedas G.J.A., Buynak E.B., Hilleman M.R. Trivalent combined measles-mumps-rubella (M-M-R) vaccine. Findings in clinical-laboratory studies. J. Am. Med. Assoc. 218:1971;57-61.
47. Hilleman MR, Weibel RE, Villarejos VM, Buynak EB, Stokes Jr. J, Arguedas GJA, Vargas AG. Combined live virus vaccines. PAHO Sci. Publ. 1971; No. 226: 397-400.
48. Report to the Centers for Disease Control and Prevention. Cost benefit analysis of the measles-mumps-rubella (MMR) vaccine. Arlington, VA: Battelle; May 14 1994.
49. Neff B.J., et al. Clinical and laboratories studies of KMcC strain live attenuated varicella virus. Proc. Soc. Exp. Biol. Med. 166:1981;339-347.
50. Takahashi M., Asano Y., Kamiya H., Baba K. Varicella vaccine: case studies. Microbiol. Sci. 2:1985;249-254.
51. Okazaki W., Purchase H.G., Burmester B.R. Protection against Marek's disease by vaccination with a herpesvirus of turkeys. Avian. Dis. 14:1970;413-429.
52. Hilleman M.R. Marek's disease vaccine: its implication in biology and medicine. Avian. Dis. 16:1972;191-199.
53. Mascoli C.C., Ittensohn O.L., Villarejos V.M., Arguedas G.J.A., Provost P.J., Hilleman M.R. Recovery of hepatitis agents in the marmoset from human cases occurring in Costa Rica. Proc. Soc. Exp. Biol. Med. 142:1973;276-282.
54. Provost P.J., Ittensohn O.L., Villarejos V.M., Arguedas G.J.A., Hilleman M.R. Etiologic relationship of marmoset propagated CR326 hepatitis A virus to hepatitis in man. Proc. Soc. Exp. Biol. Med. 142:1973;1257-1267.
55. Simons J.N., et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc. Natl. Acad. Sci. USA. 92:1995;3401-3405.
56. Hilleman M.R., Provost P.J., Miller W.J., Villarejos V.M., Ittensohn O.L., McAleer W.J. Immune adherence and complement-fixation tests for human hepatitis A. Diagnostic and epidemiologic investigations. Dev. Biol. Stand. 30:1975;383-389.
57. Hilleman M.R., Provost P.J., Wolanski B.S., Miller W.J., Ittensohn O.L., McAleer W.J. Characterization of CR326 human hepatitis A virus, a probable enterovirus. Dev. Biol. Stand. 30:1975;418-424.
58. Hilleman M.R. Hepatitis and hepatitis A vaccine: a glimpse of history. J. Hepatol. 18:1993;S5-S10.
59. Provost P., Hilleman M.R. An inactivated hepatitis A virus vaccine prepared from infected marmoset liver. Proc. Soc. Exp. Biol. Med. 159:1978;201-203.
60. Provost P.J., Hilleman M.R. Propagation of human hepatitis A virus in cell culture in vitro. Proc. Soc. Exp. Biol. Med. 160:1979;213-221.
61. Lewis J.A., et al. Use of a live attenuated hepatitis A vaccine to prepare a highly purified formalin inactivated hepatitis A vaccine. Hollinger F.B., Lemon S.M., Margolis H., et al. Viral hepatitis and liver disease. 1991;94-97 Williams & Wilkins, Baltimore.
62. Werzberger A., et al. A controlled trial of formalin-inactivated hepatitis A vaccine in healthy children. New Engl. J. Med. 327:1992;453-457.
63. Provost P.J., et al. New findings in live attenuated hepatitis A vaccine development. J. Med. Virol. 20:1986;165-175.
64. Hilleman M.R., Buynak E.B., Roehm R.R., Tytell A.A., Bertland A.U., Lampson G.P. Purified and inactivated human hepatitis B vaccine: progress report. Am. J. Med. Sci. 270:1975;401-404.
65. Buynak E.B., Roehm R.R., Tytell A.A., Bertland A.U., Lampson G.P., Hilleman M.R. Vaccine against human hepatitis B. J. Am. Med. Assoc. 235:1976;2832-2834.
66. Hilleman M.R., Buynak E.B., McAleer W.J., McLean A.A., Provost P.J., Tytell A.A. Hepatitis A and hepatitis B vaccines. Szmuness W., Alter H.J., Maynard J. Viral Hepatitis 198l International Symposium. 1982;385-397 The Franklin Institute Press, Philadelphia.
67. Hilleman M.R. Plasma-derived hepatitis B vaccine: a breakthrough in preventive medicine. Ellis R.W. Hepatitis B vaccines in clinical practice. 1979;17-39 Marcel Dekker, New York.
68. Hilleman M.R. Immunology vaccinology and pathogenesis of hepatitis B. Koprowski H., Oldstone M.B.A. Microbe hunters then and now. 1996;221-233 Medi-Ed Press, Bloomington, IL.
69. Hilleman M.R. Three decades of hepatitis vaccinology in historic perspective: a paradigm of successful pursuits. Plotkin S., Fantini B. Vaccinia, vaccination and vaccinology: Jenner, Pasteur and their successors. 1996;199-209 Elsevier, Paris.
70. Szmuness W., Stevens C.E., Zang E.A., Harley E.J., Kellner A. A Controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1:1981;377-385.
71. Valenzuela P., Medina A., Rutter W.J., Ammerer G., Hall B.D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 298:1982;347-350.
72. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature. 307:1984;178-180.
73. Hilleman M.R., Weibel R.E., Scolnick E.M. Recombinant yeast human hepatitis B vaccine. J Hong Kong Med. Assoc. 37:1985;75-85.
74. Jacobson R.M. The current status of the rotavirus vaccine. Vaccine. 17:1999;1690-1699.
75. La Montagne JR. In: Baker PJ, editor. The Jordan report: accelerated development of vaccines, 1996. Bethesda, MD: US National Institute of Allergy and Infectious Diseases, National Institutes of Health, 1996. pp. 79.
76. La Montagne JR. The Jordan report: accelerated development of vaccines. Bethesda, MD: US National Institute of Allergy and Infectious Diseases, National Institutes of Health, 1998. pp. 126.
77. Paluka K., Banchereau J. Dendritic cells: a link between innate and adaptive immunity. J. Clin. Immunol. 19:1999;12-25.
78. Arntzen CJ. Edible vaccines produced in transgenic plants. In: Baker PJ, editor. The Jordan report: accelerated development of vaccines, 1996. Bethesda, MD: US National Institute of Allergy and Infectious Diseases, National Institutes of Health, 1996. pp. 43-48.
79. Suhrbier A. Multi-epitope DNA vaccines. Imm. Cell Biol. 75:1997;402-408.